Prostate Cancer - Results from #120

Advances in PSMA-Targeted Radionuclide Therapeutics. April 3, 2025

Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS. April 3, 2025

PSMA-PET guided Intra-prostatic Boost in Prostate SBRT (PROBE): A phase II trial. April 3, 2025

Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients. April 2, 2025

Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With Prostate Cancer: A Focus on Asian American and Pacific Islander Patients. April 2, 2025

Racial variation in the advanced prostate cancer genome. April 2, 2025

Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer. April 2, 2025

Causes of evolutionary divergence in prostate cancer. April 2, 2025

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. April 1, 2025

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. April 1, 2025

Emulating an Existing Trial of Treatments for Prostate Cancer Using Real-World Data: Challenges and lessons learned. April 1, 2025

Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. April 1, 2025

The Use of PI-FAB Score in Evaluating mpMRI After Focal Ablation of Prostate Cancer: Is It Reliable? Inter-Reader Agreement in a Tertiary Care Referral University Hospital. April 1, 2025

Patterns of Care and Treatment Outcomes Among Men Diagnosed with Prostate Cancer from Culturally and Linguistically Diverse Backgrounds: A Scoping Review. April 1, 2025

Curium Completes the Acquisition of Monrol as Part of Its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint March 31, 2025

The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review. March 31, 2025

Transperineal Focal Laser Ablation of the Prostate for Prostate Cancer: A Systematic Review of the Literature. March 31, 2025

Developments in Ultrasound-Based Imaging for Prostate Cancer Detection. March 31, 2025

Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer. March 31, 2025

A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer. March 31, 2025

Page 7 of 1474